TickerFacts.

RxSight, Inc. (RXST): Cost of Revenue

Annual figures by period end, from SEC filings.

$31.47M
Year ended 2025-12-31
$28.71M
Trailing 12 months to 2026-06-30
+4.4%
3-year compound annual growth
+19.4%
5-year compound annual growth
$40.98M2020-12-31: $12.97M2021-12-31: $18.08M2022-12-31: $27.68M2023-12-31: $35.31M2024-12-31: $40.98M2025-12-31: $31.47M$31.47M
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$31.47M-23.2%2026-02-25, From 2025-01-01
2024-12-31$40.98M+16.1%2026-02-25, From 2024-01-01
2023-12-31$35.31M+27.6%2026-02-25, From 2023-01-01
2022-12-31$27.68M+53.1%2025-02-25, From 2022-01-01
2021-12-31$18.08M+39.3%2023-03-06, From 2021-01-01
2020-12-31$12.97Mn/a2022-03-08, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Ophthalmic Goods), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
RxSight, Inc. (RXST)2025-12-31$31.47M-23.2%
Staar Surgical Co (STAA)2026-01-02$57.02M-23.3%
Warby Parker Inc. (WRBY)2025-12-31$401.33M+16.5%
Cooper Companies, Inc. (COO)2025-10-31$1.41B+8.5%
Innovative Eyewear Inc (LUCY)2025-12-31$2.09M+47.4%

Compare RXST, STAA, WRBY, COO side by side · Screen every company in Ophthalmic Goods ↗